For our annual "The Lucky 13" portfolio, we attempt to select stocks that exhibit high-quality, offer good value, and have attractive dividend yields, explains dividend and value investing expert Kelley Wright, editor of IQ Trends.
Hopefully, those characteristics will provide both safe, and excellent returns over the coming year and years to follow.
Abbott Laboratories (ABT) is a well-established, global health care company with an S&P ����Quality Ranking. Fiscal year free operating cash flow is three times its dividend, which is no surprise for this long-time Dividend Aristocrat. A solid anchor position for any portfolio.
Baxter International (BAX), another defensive anchor position, has an S&P ��+��Quality Ranking and outstanding annual dividend growth. Its return on equity for the trailing twelve months and five-year average are 29.31 and 30.42, respectively.
ConocoPhillips (COP) is into the second phase of its multi-year makeover. Having disposed of over $12 billion in unwanted assets, the company is now focused on growth. By all measures, COP is well on its way to challenging the giants in the oil and gas industry.
Top 5 Gold Companies To Watch For 2015: Steamships Trading Company Ltd(PNG)
Steamships Trading Company Limited operates as a diverse trading conglomerate in Papua New Guinea. It involves in shipping, road transport, product manufacture, property, hotels, and information technology businesses. The company?s shipping business includes operation of a fleet of coastal vessels, and providing estuarine and river trades in the Gulf and Western Provinces; short and long term vessel charters, and cargo liner services using vessels ranging from 500DWT to 6000DWT; and stevedoring and shipping agency services. Its road transport business comprises general transport, fuel distribution, and long haul transport services; and customs clearance, handling equipment hire, integrated logistics, and specialist transportation services. Steamships Trading Company?s product manufacture business includes the production and distribution of food stuff comprising ice cream, vegetable oils, condiments, and seasonings; health and beauty goods; and spirits and premixed drinks , as well as involves in distributing imported wines and spirits. Its property business comprises residential, commercial, and industrial property development and leasing activities. The company?s hotel business engages in operating hotels. Its information technology business provides business-critical ICT consulting, solutions and services, IT outsourcing, business process outsourcing, Internet services, electronics and computer retail, and training and wide-ranging technical support. The company was founded in 1924 and is based in Port Moresby, Papua New Guinea. Steamships Trading Company Limited is a subsidiary of John Swire & Sons (PNG) Limited.
Advisors' Opinion:- [By Aaron Levitt]
And more could be in store. PAA has just agreed to swallow its former natural gas storage spinoff PAA Natural Gas Storage (PNG) in a $1.41 billion deal that will instantly be accretive to PAA shareholders. Meanwhile, Plains continues to build new capacity and crude-by-rail services in key refining markets like California.
- [By Jon C. Ogg]
Plains All American Pipeline L.P. (NYSE: PAA) was maintained as Outperform with a $64 price target (versus $51.44 current) after its announced acquisition of affiliated PAA Natural Gas Storage L.P. (NYSE: PNG) in an all-stock buyout.
5 Best Defensive Stocks To Invest In 2014: Re/Max Holdings Inc (RMAX)
Re/Max Holdings, Inc., incorporated on June 25, 2013, is a franchisor of real estate brokerage services. Its business is to recruit and retain agents and sell franchises. The Company operates in two business segments: Real Estate Franchise Services, and Brokerage and Other. The Company operates in the real estate brokerage franchise industry in more than 90 countries, including the United States and Canada. Effective December 31, 2012, the Company acquired certain assets of RE/MAX of Texas. Effective November 30, 2012, the Company sold substantially all of the assets of owned and operated regional franchising operations located in Eastern Australia and New Zealand and entered into regional franchising agreements with new independent owners of these regions.
The Real Estate Franchise Services reportable segment comprises the operations of its owned and independent global franchising operations. The Brokerage and Other reportable segment contains the operations of its 21 owned brokerage offices in the U.S. which represent less than 1% of RE/MAX brokerages in the U.S., the results of operations of a mortgage brokerage company in which the Company owns a non-controlling interest, the elimination of intersegment revenue and other consolidation entities, as well as corporate and professional services expenses.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Re/Max Holdings (RMAX) have surged out of the gate as investors scoop up shares following the real-estate brokers IPO.
ReutersShares of Re/Max priced at $22, above the range of $19-$21 it had been seeking. The Associated Press has the details:
Re/Max Holdings Inc. has raised $220 million in an initial public offering of its common stock.
Re/Max is giving the underwriters a 30-day option to buy up to an additional 1.5 million shares to cover any excess demand.
The company anticipates about $194.2 million in net proceeds, after underwriting discounts and commissions and estimated offering expenses. Re/Max plans to use the proceeds to reacquire regional Re/Max franchise rights in some markets, redeem preferred membership interests and buy back ownership stakes from existing shareholders.
�Re/Max shares have jumped 21% to $26.67 at 10:32 a.m. Investors might want to reconsider jumping in, however. Here’s what I wrote about IPOs�back in 2011 and it still stands today.The IPO game is notoriously dicey for retail investors. That’s because most of the shares sold at the low offering price go to institutions; only about 20% go to individuals, according to Jay Ritter, a finance professor at the University of Florida.
That means most people must settle for buying new shares during their first few days of trading��rom the bigger investors who are selling. This scenario proved disastrous for investors who bought hot Internet companies near the end of the dot-com boom, just before they crashed.
Most IPOs, in fact, fail to pan out for small investors. Excluding the first day of trading, the average IPO underperforms similarly sized companies by 3.4 percentage points a year during its first five years of trading, according to Prof. Ritter’s data.
The IPO has a mixed impact on other real-estate related companies.�Realogy (RLGY) has fallen 0.2% to $43.62, while Vector Group (VGR), wh
- [By Sue Chang]
RE/MAX Holdings Inc. (RMAX) �is likely to report earnings of 26 cents a share in the first quarter.
- [By Eric Volkman]
Getty Images/Cultura As more than a few finance industry professionals will happily brag, 2013 was a banner year for initial public offerings with 156 new stocks coming to market -- the most since 2007 -- collectively reaping the issuers aggregate proceeds of more than $38 billion. We went over the most recognizable members of this year's rookie class in "The 5 Most Unfortgettable IPOs of 2013." But in a big pool of 156 companies, there are bound to be at least a few struggling fish. Here, then, is a selection of five from the class of 2013 that are getting seriously lapped by their peers. 1. Prosensa (RNA) This Dutch clinical-stage biopharmaceutical firm had a strong debut when it listed on the Nasdaq in late June. The stock's offer price of $13 zoomed to close at over $19 on the first day of trading. But bad news was waiting around the corner; less than three months later, the shares tanked by more than 70 percent after the company announced that the muscular dystrophy treatment (drisapersen) it was developing in partnership with GlaxoSmithKline (GLAXF), did not hit its primary endpoint in late-stage trials. That one-day free fall saw the stock swoon from $24 per share to barely over $7. Since then, shares have slipped even further, and can currently be had for less than $5. 2. Violin Memory (VMEM) As a provider of high-speed data storage solutions, this company should be well in tune with current IT needs. But it fell flat from the beginning -- on its first day of trading the stock closed slightly over $7 a share, after pricing at $9. Worse was to come when the firm reported its first quarterly results as a publicly traded entity. While revenue advanced nearly 40 percent on a year-over-year basis, that couldn't cover the gaping hole of a bottom line loss totaling $34 million (a figure, by the way, significantly higher than the top line number of $28 million). The already-sinking shares continued to dive, bottoming at just over $2.50 per share. The re
5 Best Defensive Stocks To Invest In 2014: Triangle Capital Corporation (TCAP)
Triangle Capital Corporation is a private equity and venture capital firm specializing in leveraged buyouts, management buyouts, ESOPs, change of control transactions, acquisition financings, growth financing, and recapitalizations in lower middle market companies. The firm prefers to make investments in many business sectors including manufacturing, distribution, transportation, energy, communications, health services, restaurants, media, and others. It primarily invests in companies located throughout the United States, with an emphasis on the Southeast and Midatlantic. The firm typically invests between $5 million and $20 million per transaction, in companies having annual revenues between $10 million and $200 million and an EBITDA between $3 million and $20 million and can also co-invest. It primarily invests in senior subordinated debt securities secured by second lien security interests in portfolio company assets, coupled with equity interests. The firm also invests in senior debt securities secured by first lien security interests in portfolio companies. Triangle Capital Corporation was founded in 2002 and is based in Raleigh, North Carolina.
Advisors' Opinion:- [By Eric Volkman]
Triangle Capital (NYSE: TCAP ) is continuing to set aside money to return to shareholders. The company has declared its latest quarterly dividend, which is to be $0.54 per share paid on June 26 to shareholders of record as of June 12. That amount matches the firm's previous distribution, which was paid in late March. Prior to that, it handed out $0.53 per share.
- [By Helix Investment Research]
Much has been made over Keating Capital's fee structure, and suggestions that company executives are using it as a "personal ATM" to funnel shareholder money to Keating Investments, Keating Capital's investment adviser (Keating Capital is an externally managed business development company). However, Keating's fees are not exorbitant, at least in comparison to the industry average. Per data sourced from Triangle Capital (TCAP), the average externally managed BDC has a management fee of 1.75%-2% of gross assets, and an incentive fee of 20%. Keating Capital's fee structure includes a 2% management fee, and a 20% incentive fee, in line with the industry average. The formula below represents Keating Capital's incentive fee:
- [By BDC Buzz]
FDUS is one of the few BDCs to consistently grow its NAV on a quarterly basis over the last two years. This is because most BDCs are regulated investment companies ("RIC") required to distribute at least 90% of capital gains, dividends and interest to shareholders to avoid taxation at the corporate level and 98% of net investment income to avoid paying a 4% excise tax. Excluding American Capital (ACAS) which converted from a RIC to a Subchapter C and does not pay a dividend, only a few BDCs have been able to pay a healthy dividend while increasing value per share - as discussed in "Triangle Capital: Is It Priced For Total Return?" including Main Street Capital (MAIN) and Triangle Capital (TCAP).
5 Best Defensive Stocks To Invest In 2014: BIND Therapeutics Inc (BIND)
BIND Therapeutics, Inc., incorporated on May 19, 2006, is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC).
Accurins represent the evolution of targeted therapies and nanomedicine. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. The four components include Targeting ligands, Stealth and protective layer, Controlled-release polymer matrix and Therapeutic payload. The Company focuses to use its medicinal nanoengineering platform to develop Accurins in several therapeutic areas, with an initial focus on the treatment of various types of cancer. In addition, the Company entered into collaboration agreements with several biopharmaceutical companies to develop and commercialize Accurins that are based on its collaborators��therapeutic payloads. The Company�� programs include BIND-014, solid tumor accurin and hematologic cancer accurin.
Advisors' Opinion:- [By John Udovich]
Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.
- [By John Udovich]
If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:
- [By Anna Prior]
Bind Therapeutics sa(BIND)id a collaboration with Amgen Inc.(AMGN) has been ended after both companies agreed not to pursue an option to jointly develop a molecularly targeted cancer therapy. Bind Therapeutics shares fell 11% to $11.50 premarket.
No comments:
Post a Comment